Cartesian Therapeutics, Inc. · NASDAQ:RNAC
Cartesian Therapeutics — Selecta Biosciences — Technical Presentation (June 2018)
14 slides from Cartesian Therapeutics's technical presentation, Jun 15, 2018
Slide 1: New SEL-212 Phase 2 Data Presented at EULAR
New SEL-212 Phase 2 Data Presented at EULAR June 15, 2018
Slide 2: Safe Harbor / Disclaimer
Safe Harbor / Disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, the progress of the Phase 1/2 clinical program of SEL-212, the ability of SVP-Rapamycin to mitigate unwanted imm
Slide 3: SEL-212 Phase 2 Overview and Summary of New Data Presented at EULAR
SEL-212 Phase 2 Overview and Summary of New Data Presented at EULAR Summary of new data presented at EULAR • 3-month data show SEL-212 product profile may provide: • Mitigation of ADAs enabling repeat dosing and sustained serum uric acid control: ~81% of patients with sUA <6 mg/dl • Low flare rate i
Slide 4: Current Stage of SEL-212 Clinical Development Plan
Current Stage of SEL- SEL-212 Clinical Development Plan 212 Development DETERMINATION OF DOSE REGIMEN TO TAKE INTO PHASE 3 PHASE 3 PROGRAM WITH DEFINED DOSE REGIMEN Phase 1 a Dose Finding Phase 2 Dose Ranging Pegsiticase Five monthly injections; 6 Monthly Combination Injections of SEL-212 (N= 22) in
Slide 5: Expanded Phase 2 Data at 3 Months Show 81% of Patients With Control of SUA <6 mg/dl
Expanded Phase 2 Data at 3 Months Show 81% of Patients With Control of SUA <6 mg/dl Pegsiticase + SVP-Rapamycin SEL-212 1 0 0 Pegsiticase 0.2 or 0.4 mg/kg 81% (22/27) SVP-Rapamycin 5 0 0.125 or 0.15 mg/kg 0 % Pts. SUA mg/dL SUA <6 Pts. % 0 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 Week 0.2 or 0.4 mg/kg Pegsitic
Slide 6: Cohort 10: 0.125 mg/kg of SEL-110 + 0.4 mg/kg of SEL-037
Cohort 10: 0.125 mg/kg of SEL-110 + 0.4 mg/kg of SEL-037 Patient 0.125 0.125 0.125 0 0 SEL-110 0.4 0.4 0.4 0.4 0.4 SEL-037 1 0 1 0 5 8 4 6 1 0 4 1 0 3 106-0060 2 0 1 0 2 1 0 1 0 5 8 4 6 1 0 102-0019 4 1 0 3 2 0 1 0 2 1 0 1 0 5 8 4 6 1 0 107-0012 4 3 1 0 2 0 1 0 2 1 0 1 0 5 7 of 8 evaluable patients
Slide 7: Cohort 11: 0.15 mg/kg of SEL-110 + 0.2 mg/kg of SEL-037
Cohort 11: 0.15 mg/kg of SEL-110 + 0.2 mg/kg of SEL-037 0.15 0.15 0.15 0 0 SEL-110 Patient 0.2 0.2 0.2 0.2 0.2 SEL-037 1 0 1 0 5 8 4 6 1 0 117-0003 4 3 1 0 2 0 1 0 2 1 0 1 0 5 8 4 6 1 0 106-0086 3 4 1 0 2 0 1 0 2 1 0 1 0 5 8 of 10 evaluable patients 8 4 111-0018 6 1 0 4 1 0 3 2 (80%) maintained UA c
Slide 8: Cohort 12: 0.15 mg/kg of SEL-110 + 0.4 mg/kg of SEL-037
Cohort 12: 0.15 mg/kg of SEL-110 + 0.4 mg/kg of SEL-037 0.15 0.15 0.15 0 0 SEL-110 Patient 0.4 0.4 0.4 0.4 0.4 SEL-037 1 0 1 0 5 8 4 111-0012 6 1 0 4 1 0 3 2 0 1 0 2 1 0 1 0 5 8 4 111-0013 6 1 0 4 1 0 3 2 0 1 0 2 1 2 1 0 5 1 0 8 1 0 4 111-0015 6 4 1 0 3 2 0 1 0 2 1 0 1 0 5 8 4 6 1 0 110-0028 Anti )
Slide 9: Updated EULAR-Cohort Data Continue to Show Low Overall Incidence of Gout Flares
Updated EULAR-Cohort Data Continue to Show Low Overall Incidence of Gout Flares Percent patients with gout flare by treatment month 6 0 50 4 0 33 19 2 0 8 % of Patients w/Flare w/Flare PatientsPatientsofof % % 0 month 1 1 2 3 Pegsiticase Alone SEL-212* * Pegsiticase 0.2 or 0.4 mg/kg with SVP-Rapamyc
Slide 10: Data Continue to Suggest Low Flare Rates During SEL-212 Therapy – All Phase 2 Patients
Data Continue to Suggest Low Flare Rates During SEL-212 Therapy – All Phase 2 Patients to Date % of Patients Experiencing Flares in Month 6 0 5 0 4 0 2 7 1 9 2 0 1 4 % of Patients w/Flare Patients of % 6 3 0 1 1 2 3 4 5 Pegsiticase Alone SEL-212* • Data indicate SEL-212 lowers flares initially and o
Slide 11: SEL-212 Safety For the Total Phase 2 Patient Population
SEL-212 Safety For the Total Phase 2 Patient Population •SEL-212 has been generally well tolerated at clinically active doses following >380 administrations •Seventeen SAEs reported in the ongoing Phase 2 trial: • Nine were reported not to be or unlikely to be related to study drug • Eight infusion
Slide 12: SEL-212 EULAR-Cohort Data Compared to KRYSTEXXA ACR Data
SEL-212 EULAR-Cohort Data Compared to KRYSTEXXA® ACR Data Category SEL-212 (12 weeks) KRYSTEXXA® (16 weeks)+ sUA control 81%++ 44% Gout flare % 33% 52% Dosing regimen 3 monthly injections 3 weekly followed by 7 bi-weekly injections +Krystexxa results from “Initial Clinical Study to determine whether
Slide 13: Next Step for SEL-212 in 2018
Next Step for SEL-212 in 2018 SEL-212 PHASE 3 PROGRAM • Data expected in third quarter from patients receiving 6 Monthly Combination Injections of SEL-212 against five combination placebo doses of SEL-212 • Patients now receiving 4th of 5 expected combination doses • Phase 3 program Primary Clinical
Slide 14: Thank you to patients and clinical trial investigators
We thank all of the patients that participated in our clinical trials. We are very grateful to the clinical trial site investigators and their staff.
Selecta Biosciences — Technical Presentation (June 2018) on 6ix